Mitochondria-targeted Pyrroloquinoline quinone (PQQ)can be a potential therapeutic in progressive respiratory diseases.
- Conditions
- Health Condition 1: J60-J70- Lung diseases due to external agents
- Registration Number
- CTRI/2019/08/020762
- Lead Sponsor
- CSIR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
•Patients with a clinical and / or radiological diagnosis of COPD and ILD in the Pulmonary medicine OPD and clinics.
•Definition of COPD: (a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. Exacerbations and comorbidities contribute to the overall severity in individual patients). Classification of severity will be done based on GOLD 2018 criteria using spirometry according to ATS / ERS recommendations (2005).
•Definition of ILD: (patients with diagnosis of ILD based on clinical features, spirometry and radiological (HRCT chest) basis. All types of ILD will be included. Adult subjects
1. Patients other diseases such as lung cancer or pulmonary tuberculosis will be excluded from this study.
2. Pregnant women will be excluded from this study.
3. Patients not willing to give consent will be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome of this program is at least one drug candidate (new or repurposed) at an advanced level of development (efficacy in human trial or large animal). The program will also build capacity and enhance scientific understanding of respiratory diseases.Timepoint: 6 months
- Secondary Outcome Measures
Name Time Method pon successful completion of the project, give a potential therapeutics for respiratory disease like COPD and IPF.Timepoint: 6 months